Paediatric follow-up of haemodynamically insignificant congenital cardiac lesions

Benjamin G Smith1, Shakeel A Qureshi

  • 1Department of Paediatric Cardiology, Royal Hospital for Sick Children, Glasgow, United Kingdom.

Insights

Follow-up for hemodynamically insignificant congenital cardiac lesions (HICCL) in the UK varies widely. A rationalized approach suggests limited follow-up after age two, with only two assessments recommended for most HICCL cases.

Area of Science:

  • Pediatric Cardiology
  • Congenital Heart Disease
  • Echocardiography

Background:

  • Hemodynamically insignificant congenital cardiac lesions (HICCL) represent a spectrum of heart conditions in children.
  • Current follow-up practices for HICCL in the UK are not standardized.
  • Advanced echocardiography may lead to over-investigation and prolonged follow-up.

Purpose of the Study:

  • To describe current follow-up practices for HICCL in the UK.
  • To propose a rationalized follow-up strategy based on the natural history of these lesions.

Main Methods:

  • An internet-based survey was conducted among 170 UK pediatric cardiologists and general pediatricians.
  • Respondents were presented with five common HICCL scenarios: VSD, ASD, PFO, mild PS, and PDA.
  • 52 responses were analyzed to identify trends in follow-up beliefs and practices.

Main Results:

  • Significant variation in follow-up practices for HICCL was observed among respondents.
  • A tendency to discharge patients with patent foramen ovale (PFO) was noted.
  • Most other HICCL lesions were followed, often with frequent reviews.

Conclusions:

  • Over-reliance on advanced echocardiography may result in unnecessary frequent reviews of HICCL.
  • A rationalized follow-up protocol is proposed, recommending no more than two assessments after age two for most HICCL.
  • These recommended assessments should occur in late childhood and near full growth.
Abstract

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...